John Hooper

John Hooper is a prominent researcher in cancer molecular biology, affiliated with the Faculty of Science and the School of Biomedical Sciences at Queensland University of Technology. His work centers on the role of proteases, particularly serine proteases and CDCP1, in cancer progression and therapy. With a publication record spanning over two decades, he has contributed significantly to understanding proteolytic signaling in ovarian, prostate, and colorectal cancers.

His research interests include Cancer Biology, Protease Signaling, CDCP1, Kallikrein-Related Peptidases, and Targeted Cancer Therapy. He has extensively studied how proteases like KLKs and membrane serine proteases regulate cell signaling via PARs and contribute to tumor dissemination. A major focus has been on CDCP1, a cell surface glycoprotein that promotes metastasis and is now being explored as a therapeutic and imaging target.

The recent publications (2020–2025) demonstrate a strong trend toward translational research, including the development of anti-CDCP1 immuno-conjugates, imaging tracers, and metabolic targeting in ovarian and breast cancers. His work increasingly integrates preclinical models, molecular imaging, and combination therapies to overcome drug resistance.

John Hooper has collaborated with leading researchers in oncology and molecular biology. While no formal awards are listed, his work has been published in high-impact journals such as Oncogene, Clinical Cancer Research, and Theranostics. He has contributed to major collaborative projects, including the PRACTICAL consortium on prostate cancer genetics.

He has mentored or collaborated with numerous researchers, though specific students are not listed. His lab or research group appears to focus on protease biology and cancer signaling pathways, often using biochemical, cellular, and in vivo models to validate therapeutic targets.